Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This is a two phase study investigating combinations of pharmacological and behavioral
interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase
will assess strategies for improving retention on buprenorphine (BUP) and extended-release
injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are
most likely to lead to long-term success (absence of relapse), and what characteristics of
participants distinguish those who can safely discontinue Medications for Opioid Use Disorder
(MOUD) from those who remain at risk of relapse and should not discontinue.
Phase:
Phase 2
Details
Lead Sponsor:
NYU Langone Health
Collaborators:
Columbia University Columbia University Irving Medical Center Harvard Medical School Harvard Medical School (HMS and HSDM) Mclean Hospital National Institute on Drug Abuse (NIDA) New York State Psychiatric Institute The Emmes Company The Emmes Company, LLC